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367 Intestinal current measurement as a diagnostic procedure in
cystic ﬁbrosis in infants and young children
M. Wilschanski1, Y. Yaakov1, G. Stern1, D. Shoseyov1, L. Bentur2, S. Goldberg3,
E. Shachar1, E. Kerem1. 1CF Center, Hadassah University Hospital, Jerusalem,
Israel; 2CF Center, Meyer Children’s Hospital, Haifa, Israel; 3CF Center, Shaare
Zedek Medical Center, Jerusalem, Israel
Aim: Assessing functional CFTR activity using nasal potential difference mea-
surement is becoming an integral component of CF diagnosis in non-classical
presentations. We present our experience of an alternative method of assessing
functional CFTR activity, which involves intestinal current measurement (ICM) of
rectal biopsies, thereby removing the age-limitation from this useful diagnostic aid.
Methods: Rectal biopsies were taken from 3 sets of patients: known CF, controls,
and suspected CF. This last group included patients with a mean age 3.4±3 years,
who were undergoing investigation for a variety of symptoms including recurrent
pneumonia, unexplained bronchiectasis, chronic diarrhea and failure to thrive. ICMs
were then performed using standard protocols by mounting the rectal biopsy in
an Ussing chamber and sequentially adding secretagogues while recording current
changes.
Results: Comparing the ICMs of the known CF group and the controls revealed
a signiﬁcant difference on addition of the chloride channel activators: Carbachol
(p< 0.0001), histamine (p< 0.0001) and cAMP + forskolin (p = 0.003). 7/22 resem-
bled the CF group and 15/22 the control group. There was no difference in sweat
tests between these groups.
Conclusion: ICM tests may be useful to differentiate between CF and non-
CF patients, in particular in those young patients with atypical presentations, in
whom performing nasal PD is impractical. Larger studies are needed to conﬁrm
these results.
368 Nasal potential difference testing in the diagnostic algorithm
of CF
P.G. Middleton, J.R. Bishop. Ludwig Engel Centre for Respiratory Research,
Westmead Hospital, Westmead, Sydney, NSW, Australia
Since newborn screening for CF in Sydney started in 1981, a cohort of adolescents
and adults have been assessed and reassured that they do not have classical CF.
However, some are now presenting in adulthood with recurrent chest infections,
sinusitis and other manifestations suggestive of CF. If sweat tests or genotype
analysis are positive, a diagnosis can be made, but exclusion of mild CF is difﬁcult.
In this situation the nasal potential difference (PD) technique can provide useful
diagnostic information.
This abstract summarises our diagnostic experience with the nasal PD in >70 pa-
tients over the last 10 years at Westmead Hospital.
Methods: A standard diagnostic protocol has been used (Eur Respir J 1994;7:2050–
2056). To measure sodium transport, the baseline (unstimulated) nasal PD and
the response to amiloride are measured. Chloride transport is assessed using the
responses to low chloride and isoprenaline solutions.
Results: The majority of patients have shown normal nasal PD responses, effec-
tively excluding CF. Some new CF patients have been diagnosed, including some
with normal lung function and borderline/normal sweat electrolytes. However, in
3 patients the nasal PD response was equivocal.
Conclusion: The nasal PD provides important information to both diagnose and
exclude CF, aiding the investigation of adolescents and adults with CF like disease.
However, nasal PD testing in this ‘mild’ group can still be inconclusive, highlighting
the need for continued observation and followup.
Supported by: Cystic Fibrosis Australia and the National Health & Medical
Research Council (NH&MRC).
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An important issue of CF neonatal screening is the classiﬁcation of children with
persistent hypertrypsinemia, “borderline” sweat test results and unconclusive CFTR
genotyping As part of an ongoing study, we performed NPD in 13 children – mean
age: 18 (6−36) months – referred for persistent hypertrypsinemia and/or borderline
sweat test after neonatal screening.
Three infants, subsequently diagnosed with CF on the basis of a CF genotype
had typical CF results. Three other children did not have a CF-causing genotype
after extensive genetic screening and had a nasal PD proﬁle similar to the values
reported in the healthy children (. Six of the 7 remaining children were compound
heterozygotes for known but rare and wide-spectrum CFTR mutations (F508del and
R933G, R1070W, R117H-7T, R347H, G622D and L206W-A559T. Four patients had
low to absent change in PD proﬁle after isoproterenol (DCl− free-isoproterenol =
−0.8 (−3−0.5)mV). They had a symptomatic lung disease, with recurrent bronchial
infection and Pseudomonas aeruginosa or Staphylococcus aureus colonisation.
Three other patients had PD measurements within the normal values and were
asymptomatic.
The identiﬁcation of a subgroup of asymptomatic children with residual CFTR
Cl− transport raises the question whether these patients might develop, if any,
an atypical, mild CF disease. The patients with questionable CF after neonatal
screening should be systematically investigated with NPD and closely followed-up
in specialized CF centers to clarify the diagnosis and prognosis value of this test
in such situations.
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Aim: The association between the phenotype of recurrent pancreatitis and cystic
ﬁbrosis transmembrane conductance regulator (CFTR) dysfunction is unclear.
Methods: Patients with idiopathic recurrent pancreatitis were referred for electro-
physiological investigation.
Results: 33 patients (18 males) aged 20±12 years with recurrent pancreatitis were
studied. 3 patients had mild asthma and one patient had ulcerative colitis. There
was no family history of CF. All patients were PS, had normal spirometry and
negative sputum cultures and had normal imaging of the pancreatic duct by ERCP
or MRCP. Mean sweat chloride values were 41±14meq/L (range 18−66). Nasal
Potential Difference measurement (NPD) was pathological in 7 patients. Mean
basal potential difference (PD) in these 7 patients was −33±13mV and there was
an abnormal response to chloride-free and isoproterenol solutions. There was no
difference in sweat chloride concentration between the 2 groups. Mutation analysis
revealed W1282X/5T, D1152H/5T and W1282X/− in 3 patients with abnormal NPD
and one W1282X allele was found in one patient with normal NPD. Summary: In
this series, 21% of patients with recurrent pancreatitis have abnormalities of CFTR
function.
Conclusion: Patients presenting with recurrent, “idiopathic” pancreatitis require
CFTR function testing.
